» Articles » PMID: 27771773

Case-control Study of Candidate Gene Methylation and Adenomatous Polyp Formation

Overview
Date 2016 Oct 25
PMID 27771773
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Colorectal cancer (CRC) is one of the most common and preventable forms of cancer but remains the second leading cause of cancer-related death. Colorectal adenomas are precursor lesions that develop in 70-90 % of CRC cases. Identification of peripheral biomarkers for adenomas would help to enhance screening efforts. This exploratory study examined the methylation status of 20 candidate markers in peripheral blood leukocytes and their association with adenoma formation.

Methods: Patients recruited from a local endoscopy clinic provided informed consent and completed an interview to ascertain demographic, lifestyle, and adenoma risk factors. Cases were individuals with a histopathologically confirmed adenoma, and controls included patients with a normal colonoscopy or those with histopathological findings not requiring heightened surveillance (normal biopsy, hyperplastic polyp). Methylation-specific polymerase chain reaction was used to characterize candidate gene promoter methylation. Odds ratios (ORs) and 95 % confidence intervals (95% CIs) were calculated using unconditional multivariable logistic regression to test the hypothesis that candidate gene methylation differed between cases and controls, after adjustment for confounders.

Results: Complete data were available for 107 participants; 36 % had adenomas (men 40 %, women 31 %). Hypomethylation of the MINT1 locus (OR 5.3, 95% CI 1.0-28.2) and the PER1 (OR 2.9, 95% CI 1.1-7.7) and PER3 (OR 11.6, 95% CI 1.6-78.5) clock gene promoters was more common among adenoma cases. While specificity was moderate to high for the three markers (71-97 %), sensitivity was relatively low (18-45 %).

Conclusion: Follow-up of these epigenetic markers is suggested to further evaluate their utility for adenoma screening or surveillance.

Citing Articles

Screening and identifying of biomarkers in early colorectal cancer and adenoma based on genome-wide methylation profiles.

He C, Huang Q, Zhong S, Chen L, Xiao H, Li L World J Surg Oncol. 2023; 21(1):312.

PMID: 37779184 PMC: 10544418. DOI: 10.1186/s12957-023-03189-1.


The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer.

Pourali G, Ahmadzade A, Arastonejad M, Pourali R, Kazemi D, Ghasemirad H Mol Cell Biochem. 2023; 479(5):1243-1255.

PMID: 37405534 DOI: 10.1007/s11010-023-04790-4.


Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review.

Raut J, Guan Z, Schrotz-King P, Brenner H Cancers (Basel). 2019; 11(7).

PMID: 31261771 PMC: 6678372. DOI: 10.3390/cancers11070912.


Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel.

Fernandez-Rozadilla C, Kartsonaki C, Woolley C, McClellan M, Whittington D, Horgan G Br J Cancer. 2018; 118(5):727-732.

PMID: 29438375 PMC: 5846076. DOI: 10.1038/bjc.2017.486.


Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China.

Liu Y, Wang Y, Hu F, Sun H, Zhang Z, Wang X Oncotarget. 2017; 8(37):61239-61252.

PMID: 28977860 PMC: 5617420. DOI: 10.18632/oncotarget.18054.

References
1.
Rashid A, Shen L, Morris J, Issa J, Hamilton S . CpG island methylation in colorectal adenomas. Am J Pathol. 2001; 159(3):1129-35. PMC: 1850474. DOI: 10.1016/S0002-9440(10)61789-0. View

2.
Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K . Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol. 2007; 102(10):2259-64. DOI: 10.1111/j.1572-0241.2007.01404.x. View

3.
Jacobs E, Van Pelt C, Forster R, Zaidi W, Hibler E, Galligan M . CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res. 2013; 73(8):2563-73. PMC: 3630267. DOI: 10.1158/0008-5472.CAN-12-4134. View

4.
Gao Y, Killian K, Zhang H, Yu K, Li Q, Weinstein S . Leukocyte DNA methylation and colorectal cancer among male smokers. World J Gastrointest Oncol. 2012; 4(8):193-201. PMC: 3423510. DOI: 10.4251/wjgo.v4.i8.193. View

5.
Adalsteinsson B, Gudnason H, Aspelund T, Harris T, Launer L, Eiriksdottir G . Heterogeneity in white blood cells has potential to confound DNA methylation measurements. PLoS One. 2012; 7(10):e46705. PMC: 3465258. DOI: 10.1371/journal.pone.0046705. View